Genprex (GNPX) Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.
UCSF and BridgeBio Pharma to Accelerate Therapies for Genetic Diseases
By Nicholas Weiler on December 22, 2020
SAN FRANCISCO – December 23, 2020 - UC San Francisco and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.
“The BridgeBio team is developing close relationships with our investigators at UCSF with the mission of bringing potential therapies into the clinic quickly, where they have the opportunity to help patients in need,” said Barry Selick, Ph.D., UCSF vice chancellor for business development, innovation and partnerships and director of the Office of Innovation Ventures. “We are excited about this partnership and the opportunities it may create for the development of new medicines.”